Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spine Tech and Orquest to combine technologies

This article was originally published in Clinica

Executive Summary

Spine Tech is to file an IDE with the US FDA to evaluate its spinal fusion devices (BAK) with Orquest's resorbable bone grafting material (Healos). Orquest's product is a porous matrix of collagen impregnated with resorbable hydroxyapatite that provides a scaffold for bone formation. The two companies plan to evaluate the material with Spine-Tech's hollow, threaded titanium alloy cylinders, which can be implanted in the spaces between vertebrae in the lumbar spine. Currently, some 80 per cent of bone grafting procedures harvest the patient's own bone, causing pain and long, expensive hospital stays.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT083415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel